Riabov, V., Xu, Q., Schmitt, N., Streuer, A., Ge, G., Bolanos, L., Wunderlich, M., Jann, J.-C., Wein, A., Altrock, E., Demmerle, M., Mukherjee, S., Ali, A. M., Rapp, F., Nowak, V., Weimer, N., Obländer, J., Palme, I., Göl, M., … Nowak, D. (2023). <i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms. Haematologica, 0–0. https://doi.org/10.3324/haematol.2023.282921

Xu, J. J., & Viny, A. D. (2024). Chromatin organization in myelodysplastic syndrome. Experimental Hematology, 134, 104216. https://doi.org/10.1016/j.exphem.2024.104216

Carson, J. L., & Brittenham, G. M. (2023). How I treat anemia with red blood cell transfusion and iron. Blood, 142(9), 777–785. https://doi.org/10.1182/blood.2022018521

Ali, A. M., BenMohamed, F., Decina, A., Mukherjee, S., Levi, S., Garrido Castillo, L. N., Bréchot, D., Jurcic, J., Raza, A., & Paterlini Bréchot, P. (2023). Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS). Medical Oncology, 40(7). https://doi.org/10.1007/s12032-023-02064-z

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794

de Botton, S., Cluzeau, T., Vigil, C., Cook, R. J., Rousselot, P., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., Jurcic, J. G., Sekeres, M. A., Savona, M. R., Roboz, G. J., Bixby, D., Madigan, K., Volkert, A., Stephens, K., Kang-Fortner, Q., … Stein, E. M. (2023). Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Advances, 7(9), 1858–1870. https://doi.org/10.1182/bloodadvances.2022008806

DiNardo, C. D., Hochhaus, A., Frattini, M. G., Yee, K., Zander, T., Krämer, A., Chen, X., Ji, Y., Parikh, N. S., Choi, J., & Wei, A. H. (2022). A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. Journal of Cancer Research and Clinical Oncology, 149(3), 1145–1158. https://doi.org/10.1007/s00432-022-03983-6

Xu, J. J., Chalk, A. M., Wall, M., Langdon, W. Y., Smeets, M. F., & Walkley, C. R. (2022). Srsf2P95H/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice. Leukemia, 36(12), 2883–2893. https://doi.org/10.1038/s41375-022-01727-6

Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A. K., Mufti, G. J., Buckstein, R., Santini, V., Shetty, J. K., Ito, R., Zhang, J., Zhang, G., Ha, X., Backstrom, J. T., & Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 140(20), 2170–2174. https://doi.org/10.1182/blood.2022016171

Lieu, Y. K., Liu, Z., Ali, A. M., Wei, X., Penson, A., Zhang, J., An, X., Rabadan, R., Raza, A., Manley, J. L., & Mukherjee, S. (2021). SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences, 119(1). https://doi.org/10.1073/pnas.2111703119